PMC:7386875 / 1146-1730 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":61,"end":65},"obj":"Body_part"},{"id":"T8","span":{"begin":175,"end":181},"obj":"Body_part"},{"id":"T9","span":{"begin":541,"end":548},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma50723"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":56,"end":65},"obj":"Body_part"},{"id":"T2","span":{"begin":61,"end":65},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0035552"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T18","span":{"begin":66,"end":76},"obj":"Disease"},{"id":"T19","span":{"begin":78,"end":96},"obj":"Disease"},{"id":"T20","span":{"begin":102,"end":108},"obj":"Disease"},{"id":"T22","span":{"begin":195,"end":211},"obj":"Disease"},{"id":"T23","span":{"begin":250,"end":258},"obj":"Disease"},{"id":"T24","span":{"begin":346,"end":354},"obj":"Disease"},{"id":"T25","span":{"begin":378,"end":388},"obj":"Disease"},{"id":"T26","span":{"begin":499,"end":507},"obj":"Disease"},{"id":"T27","span":{"begin":519,"end":529},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005279"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A21","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":61,"end":65},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T9","span":{"begin":61,"end":65},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"},{"id":"T10","span":{"begin":127,"end":137},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T11","span":{"begin":175,"end":181},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2","span":{"begin":440,"end":445},"obj":"Chemical"},{"id":"T3","span":{"begin":541,"end":548},"obj":"Chemical"},{"id":"T4","span":{"begin":555,"end":565},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":56,"end":76},"obj":"Phenotype"},{"id":"T4","span":{"begin":78,"end":96},"obj":"Phenotype"},{"id":"T5","span":{"begin":102,"end":108},"obj":"Phenotype"},{"id":"T6","span":{"begin":195,"end":211},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002625"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002204"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001297"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0001873"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T4","span":{"begin":127,"end":152},"obj":"http://purl.obolibrary.org/obo/GO_0050820"},{"id":"T5","span":{"begin":141,"end":152},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":110,"end":259},"obj":"Sentence"},{"id":"T9","span":{"begin":260,"end":416},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}

{"project":"LitCovid-PubTator","denotations":[{"id":"57","span":{"begin":541,"end":548},"obj":"Chemical"},{"id":"75","span":{"begin":22,"end":46},"obj":"Disease"},{"id":"76","span":{"begin":56,"end":76},"obj":"Disease"},{"id":"77","span":{"begin":78,"end":96},"obj":"Disease"},{"id":"78","span":{"begin":102,"end":108},"obj":"Disease"},{"id":"79","span":{"begin":195,"end":211},"obj":"Disease"},{"id":"80","span":{"begin":250,"end":258},"obj":"Disease"},{"id":"81","span":{"begin":266,"end":290},"obj":"Disease"},{"id":"82","span":{"begin":328,"end":337},"obj":"Disease"},{"id":"83","span":{"begin":346,"end":354},"obj":"Disease"},{"id":"84","span":{"begin":378,"end":388},"obj":"Disease"},{"id":"85","span":{"begin":499,"end":507},"obj":"Disease"},{"id":"86","span":{"begin":519,"end":529},"obj":"Disease"}],"attributes":[{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D006493"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D013927"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:D020246"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:D011655"},{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"MESH:D020521"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:D013921"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"MESH:C000657245"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"MESH:D013927"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"MESH:D003643"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:D013927"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"MESH:C000657245"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:D013927"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"mately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drug"}